UNCY Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

4.850

Open

4.570

VWAP

4.65

Vol

1.56M

Mkt Cap

224.90M

Low

4.450

Amount

7.26M

EV/EBITDA(TTM)

Total Shares

27.39M

151.00M

EV/OCF(TTM)

P/S(TTM)

Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.

Events Timeline

(ET)

2026-06-30

09:00:00

Markets End Cautiously, Semiconductor Stocks Drive Gains

2026-06-30

07:30:00

Unicycive Receives Complete Response Letter from FDA

2026-06-26 (ET)

2026-06-26

13:00:00

Unicycive Resubmits Drug Application, Price Target $22

2026-06-05 (ET)

2026-06-05

16:20:00

Unicycive Therapeutics Files $150M Mixed Securities Shelf

News

9.0

06-30stocktwits

PinnedUnicycive's Drug Faces Second FDA Rejection

8.5

06-30Newsfilter

PinnedUnicycive Receives Complete Response Letter from FDA

7.0

14:47 PMGlobenewswire

Block & Leviton Investigates Unicycive Therapeutics for Securities Violations

9.0

06-30seekingalpha

Unicycive Therapeutics Shares Plunge 37% After FDA Response

7.0

06-30Globenewswire

Unicycive Therapeutics Under Investigation Following FDA Response, Stock Declines

9.0

06-30stocktwits

Unicycive Faces Second FDA Rejection for Kidney Drug

5 Analyst Rating

Wall Street analysts forecast UNCY stock price to rise

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

21.00

Averages

35.80

High

60.00

Current: 0.000

Low

21.00

Averages

35.80

High

60.00

Noble Capital

Outperform

maintain

$60 -> $50

AI Analysis

2026-07-01

New

Reason

Noble Capital

Price Target

$60 -> $50

AI Analysis

2026-07-01

New

maintain

Outperform

Reason

Noble Capital lowered the firm's price target on Unicycive Therapeutics to $50 from $60 and keeps an Outperform rating on the shares after the company announced it has received a Complete Response Letter from the FDA stating that the NDA for oxylanthanum carbonate has not been approved due to a required inspection of the third-party manufacturing vendor. The firm now expects product approval around year-end 2026, the analyst tells investors.

Benchmark

Speculative Buy

downgrade

$18 -> $13

2026-07-01

New

Reason

Benchmark

Price Target

$18 -> $13

2026-07-01

New

downgrade

Speculative Buy

Reason

Benchmark lowered the firm's price target on Unicycive Therapeutics to $13 from $18 and keeps a Speculative Buy rating on the shares after the company received a new Complete Response Letter from the FDA regarding the New Drug Application for oxylanthanum carbonate, once again related to a deficiency at a third-party manufacturing vendor. The firm is shifting its model forward, noting that the company "remains optimistic" about an inspection of the third-party manufacturing vendor in the next few weeks, after which it will "expeditiously" resubmit the NDA.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for UNCY

Unlock Now

Valuation Metrics

The current forward P/E ratio for Unicycive Therapeutics Inc (UNCY.O) is 3.44, compared to its 5-year average forward P/E of -0.10. For a more detailed relative valuation and DCF analysis to assess Unicycive Therapeutics Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-0.10

Current PE

3.44

Overvalued PE

6.65

Undervalued PE

-6.85

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-6060.87

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

22439.11

Undervalued EV/EBITDA

-34560.85

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

4.03

Current PS

0.56

Overvalued PS

15.58

Undervalued PS

-7.53

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

most bullish ticker next 6 months

Intellectia · 10 candidates

Analyst Consensus: Strong BuyQuarter Eps Yoy Growth: >= 20.0%Target Price Upside Potential: MoreAbovePriceMoving Average Relationship: PriceAboveMA200One Month Predict Return: >= 8.0%

Ticker

Name

Market Cap$

SYRE

Spyre Therapeutics Inc

2.93B

GERN

Geron Corp

1.23B

AVNW

Aviat Networks Inc

314.56M

OWLT

Owlet Inc

309.45M

VRDN

Viridian Therapeutics Inc

2.68B

UNCY

Unicycive Therapeutics Inc

139.91M

low float high volume

Intellectia · 49 candidates

Region: USVolume: >= 500,000Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEFloating Shares: <= 20,000,000

Ticker

Name

Market Cap$

FAT

FAT Brands Inc

5.25M

APRE

Aprea Therapeutics Inc

5.57M

FATBB

FAT Brands Inc

27.81M

YCBD

cbdMD Inc

10.92M

LXEH

Lixiang Education Holding Co Ltd

6.50M

KXIN

Kaixin Holdings

29.77M

best strong buy for today

Intellectia · 86 candidates

Analyst Consensus: Strong BuyList Exchange: XNYS, XNAS, XASETarget Price Upside Potential: MoreAbovePriceMoving Average Relationship: PriceAboveMA20One Day Rise Prob: >= 55Monthly Average Dollar Volume: >= 500,000

Ticker

Name

Market Cap$

CING

Cingulate Inc

43.41M

CATX

Perspective Therapeutics Inc

261.77M

ELVN

Enliven Therapeutics Inc

1.51B

ADTN

ADTRAN Holdings Inc

757.90M

UTI

Universal Technical Institute Inc

1.52B

CNTA

Centessa Pharmaceuticals PLC

3.82B

Whales Holding UNCY

Logos Global Management, L.P.

Trading Trends

People Also Watch

Frequently Asked Questions

What is Unicycive Therapeutics Inc (UNCY) stock price today?

The current price of UNCY is 4.65 USD — it has decreased -0.85

What is Unicycive Therapeutics Inc (UNCY)'s business?

What is the price predicton of UNCY Stock?

Wall Street analysts forecast UNCY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for UNCY is35.80 USD with a low forecast of 21.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Unicycive Therapeutics Inc (UNCY)'s revenue for the last quarter?

Unicycive Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased

What is Unicycive Therapeutics Inc (UNCY)'s earnings per share (EPS) for the last quarter?

Unicycive Therapeutics Inc. EPS for the last quarter amounts to -0.54 USD, decreased -1450.00

How many employees does Unicycive Therapeutics Inc (UNCY). have?

Unicycive Therapeutics Inc (UNCY) has 21 emplpoyees as of July 01 2026.

What is Unicycive Therapeutics Inc (UNCY) market cap?

Today UNCY has the market capitalization of 224.90M USD.

UNCY Overview

UNCY Overview

Events Timeline

News

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Related Community Screener

Whales Holding UNCY

Trading Trends

People Also Watch

Frequently Asked Questions

What is Unicycive Therapeutics Inc (UNCY) stock price today?

What is Unicycive Therapeutics Inc (UNCY)'s business?

What is the price predicton of UNCY Stock?

What is Unicycive Therapeutics Inc (UNCY)'s revenue for the last quarter?

What is Unicycive Therapeutics Inc (UNCY)'s earnings per share (EPS) for the last quarter?

How many employees does Unicycive Therapeutics Inc (UNCY). have?

What is Unicycive Therapeutics Inc (UNCY) market cap?